Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood-Reference-Cited by-同舟云学术

Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood

Published:2018-01 Issue: Volume:51 Page:66-71
ISSN:0009-9120
Container-title:Clinical Biochemistry
language:en
Short-container-title:Clinical Biochemistry

Author:

Murata Kazunori,McCash Samuel I,Carroll Brittany,Lesokhin Alexander M,Hassoun Hani,Lendvai Nikoletta,Korde Neha S,Mailankody Sham,Landau Heather J,Koehne Guenther,Chung David J,Giralt Sergio A,Ramanathan Lakshmi V,Landgren Ola

Publisher

Elsevier BV

Subject

Clinical Biochemistry,General Medicine

Reference17 articles.

1. Interference of monoclonal antibody therapies with serum protein electrophoresis tests;McCudden;Clin. Chem.,2010

2. Sar650984, a novel humanized cd38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other cd38+ hematologic malignancies;Deckert;Clin. Cancer Res.,2014

3. Elotuzumab: a novel anti-cs1 monoclonal antibody for the treatment of multiple myeloma;Lonial;Expert. Opin. Biol. Ther.,2013

4. Upregulation of cd38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab;Nijhof;Leukemia,2015

5. International uniform response criteria for multiple myeloma;Durie;Leukemia,2006

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the clinical landscape: Update on the diagnostic and prognostic biomarkers in multiple myeloma;Molecular Biology Reports;2024-09-09

2. Evaluation of Anti-CAR Linker mAbs for CAR T Monitoring after BiTEs/bsAbs and CAR T-Cell Pretreatment;Biomedicines;2024-07-24

3. Congophilic fibrils in the glomeruli with polyclonal immunoglobulin gamma staining - another cause for diagnostic overlap: A case report;World Journal of Clinical Cases;2024-06-16

4. Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab;Clinical Biochemistry;2024-05

5. Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma;Clinical Chemistry and Laboratory Medicine (CCLM);2024-04-18